<DOC>
	<DOCNO>NCT00266799</DOCNO>
	<brief_summary>This open-label , multinational , randomize , multicenter trial design compare pegylated liposomal doxorubicin capecitabine first line chemotherapy metastatic breast cancer . The primary objective study compare time disease progression , although overall response rate , overall survival , quality life , time treatment failure , safety tolerability also assess .</brief_summary>
	<brief_title>The Efficacy Safety Pegylated Liposomal Doxorubicin Compared With Capecitabine First Line Chemotherapy Metastatic Breast Cancer ( P04445/MK-2746-071 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Patients must female . Patients must metastatic disease cytological histological confirm breast cancer . Patients must 18 year old . Patients evaluable disease ( least unidimensionally measurable lesion accord RECIST criterion least one site irradiate ) , however , patient nonmeasurable/evaluable disease exclude . Also patient bone metastasis exclude . Patients must Eastern Cooperative Oncology Group ( ECOG ) 02 . Patients must sufficient life expectancy treat chemotherapy . Patients must willing able complete study questionnaire . Patients must adequate renal function evidence serum creatinine &lt; =1.5 mg/dL , creatinine clearance &gt; =45 mL/min ( serum creatinine &gt; 1.5 mg/dL &lt; = 1.8 mg/dL ) . Patients must adequate bone marrow function evidence leukocyte count great 3.5 g/L , hemoglobin &gt; =9.0 g/dL , platelet count &gt; =100x10^9/L . Patients must adequate liver function evidence bilirubin &lt; =1.5 time upper limit normal ( ULN ) alkaline phosphatase &lt; =3 time , ULN unless relate liver metastasis . Patients must Sodium Potassium value within normal limit . Patients whose clinical condition ( comorbidity ) allow treatment monotherapy express wish treat monotherapy . Patients must sign informed consent document indicate understand purpose procedure require study willing participate study . History receive prior chemotherapy metastatic setting ( Note : patient may hormonal therapy chemotherapy adjuvant setting ; patient may receive hormonal therapy metastatic setting , patient may receive local radiotherapy ) . Patients positive estrogen / progesteronereceptor status , endocrine therapy indicate . However , patient progress hormonal therapy exclude . Patients know hypersensitivity doxorubicinhydrochlorid excipients OR know hypersensitivity capecitabine fluorouracil excipients . Patients know DPD ( dihydro pyrimidine dehydrogenase ) deficiency . Patients receive concomitant treatment sorivudine chemically related analogue , brivudine . Patients take concomitant medication ( except bisphosphonates ) metastatic disease , include hormonal therapy , radiation therapy , trastuzumab , biologicals also permit . Patients Human epidermal growth factor receptor 2 ( Her2/neu ) overexpressing tumor recent evaluation relevant result immunologically Her2neu 3+ positive Her2neu2+ positive ´Fluorescent insitu hybridization ( FISH ) ´ positive History treatment capecitabine History treatment anthracyclines adjuvant set exceed cumulative dos anthracyclines 360 mg/m^2 doxorubicin ( equivalent , i.e . 600mg/m^2 epirubicine ) . Patients anthracycline resistant disease permit . Anthracycline resistance define development locally recurrent metastatic disease adjuvant anthracycline therapy , relapse le 12 month completion anthracycline therapy . Strong remission pressure require polychemotherapy exception patient suitable treatment polychemotherapy accept polychemotherapy . Evidence primary metastatic malignancy involve central nervous system unless previously treat asymptomatic 3 month great . Patients reduce liver function ( evidence bilirubin 1.5 time upper limit normal ( ULN ) ; alkaline phosphatase 3 time ULN ( except relate liver metastasis , case &lt; =5 x ULN ) . Dyspnea exertion . History cardiac disease , New York Heart Association Class II great , clinical evidence congestive heart failure myocardial infarct within less six month leave ventricular ejection fraction ( LVEF ) 50 % . Woman childbearing potential insufficient contraception [ e.g . intrauterine device ( IUD ) regard sufficient ] study period six month follow last study drug application . All method base hormonal contraception permit . Existing pregnancy lactation ( note pregnancy test ) . A negative pregnancy test woman childbearing potential place prior randomization ( Note : A pregnancy test do patient postmenopausal . Postmenopausal define menstrual period 12 month row ) . Existing doubt ability willingness subject cooperation . Participation subject clinical study within last 30 day . Participation subject clinical study earlier date . Concomitant participation another study one described . Abuse drug , alcohol , pharmaceutical . Any condition , whether medical nonmedical , may interfere , opinion investigator , aim study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>